Cardiogen

1. Overview

Cardiogen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Arg (AEDR) and an approximate molecular weight of 489.5 Da, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a cardiac-specific bioregulator [1][5]. It belongs to the Khavinson family of peptide bioregulators -- short synthetic peptides proposed to restore age-related functional decline in their target organs through tissue-specific gene expression regulation [4][6].

The development of Cardiogen originated in the 1980s and 1990s at the Military Medical Academy in Russia, where Khavinson's group identified recurring short peptide sequences in cardiac tissue extracts [5][13]. AEDR was synthesized to reproduce the biological activity of these endogenous cardiac peptide fractions. The peptide has been studied primarily in organotypic myocardial tissue cultures and animal models, with research focusing on its effects on cardiomyocyte proliferation, apoptosis suppression, and cardiac-specific gene expression.

All published Cardiogen research is preclinical. No human clinical trials have been conducted, and no regulatory approval exists in any jurisdiction. The evidence base is concentrated almost entirely within Khavinson's research network.

Molecular Weight

~489.5 g/mol

Sequence

Ala-Glu-Asp-Arg (AEDR)

Peptide Type

Synthetic tetrapeptide bioregulator (Khavinson class)

Mechanism

Cardiomyocyte proliferation stimulation; p53-mediated apoptosis suppression; cardiac-specific gene expression regulation via DNA and histone interaction

Routes Studied

Subcutaneous, oral (capsules), culture medium (in vitro)

FDA Status

Not approved; not evaluated by any Western regulatory agency

WADA Status

Not specifically listed; falls under S0 (Non-Approved Substances)

2. Mechanism of Action

Cardiogen operates through the Khavinson bioregulator mechanism of direct nuclear peptide-DNA and peptide-histone interaction, producing tissue-specific effects in cardiac cells.

Cardiomyocyte Proliferation and Anti-Apoptosis

The most significant finding from Cardiogen research comes from the organotypic myocardial tissue culture study by Chalisova et al. (2009). At picomolar concentrations (10 to the minus 12 M), Cardiogen uniquely stimulated cardiomyocyte proliferation in tissue from both 3-month-old (young) and 24-month-old (old) rats [1]. Critically, this effect was not reproduced by any of the 20 individual naturally occurring amino acids tested at the same concentration, demonstrating that the biological activity resides in the intact tetrapeptide sequence rather than its constituent amino acids [1].

Immunohistochemical analysis revealed that Cardiogen decreased expression of the p53 tumor suppressor protein in myocardial tissue, indicating suppression of the apoptotic pathway [1]. This dual action -- stimulating proliferation while inhibiting programmed cell death -- is particularly relevant to cardiac biology, where cardiomyocyte loss through apoptosis is a hallmark of both aging and ischemic heart disease.

Histone and DNA Interaction

Like other Khavinson peptides, AEDR has been shown to bind to histone proteins H1, H2b, H3, and H4 at their N-terminal peptide-binding motifs [4]. This interaction is proposed to increase the transcriptional availability of cardiac-specific gene promoter zones, enabling expression of genes involved in myocardial differentiation and maintenance.

Short fluorescence-labeled peptides including AEDR have been demonstrated to penetrate cell nuclei in HeLa cells and interact specifically with deoxyribooligonucleotides and DNA in vitro [11]. The mechanism proposes that these peptides bypass conventional cell-surface receptors and act directly at the chromatin level.

Tissue Specificity

A distinguishing feature of Cardiogen is its cardiac tissue specificity. In studies comparing the effects of multiple Khavinson peptides across different tissue types, Cardiogen demonstrated preferential activity on cardiac tissue while showing minimal effects on non-cardiac tissues such as thymus or brain [2]. This tissue selectivity is central to the Khavinson bioregulator theory, which proposes that each organ has characteristic short peptide signals that regulate its own function [5][6].

Vascular Endothelial Effects

Cardiogen and related cardiovascular peptides have also been studied for effects on vascular endothelial cell proliferation during aging, with reported epigenetic modulation of chromatin structure and gene accessibility in endothelial cells from subjects of different ages [8].

3. Researched Applications

Cardiac Aging and Cardiomyocyte Loss

Evidence level: Preclinical (in vitro)

The primary research application for Cardiogen involves age-related cardiac tissue deterioration. In organotypic tissue cultures from old rats (24 months), Cardiogen stimulated cardiomyocyte proliferation and suppressed p53-mediated apoptosis to a degree comparable to its effects in young tissue (3 months) [1]. This suggests potential geroprotective effects on cardiac tissue, though the findings have not been extended to in vivo aging studies or human cardiac tissue.

Cardiac Differentiation and Regeneration

Evidence level: Preclinical (in vitro)

Cardiogen has been identified as a promoter of cardiac cell differentiation, with effects on transcriptional regulation and cellular architecture markers relevant to cardiomyocyte identity [3]. In the context of cardiac regeneration research, these findings are exploratory and do not yet constitute evidence of therapeutic efficacy.

Anti-Tumor Effects

Evidence level: Preclinical (animal study)

A study by Levdik and Knyazkin (2009) reported tumor-modifying effects of Cardiogen on M-1 sarcoma transplants in senescent rats, suggesting anti-tumor properties that extend beyond its cardiac-specific effects [7]. The mechanism for this anti-tumor activity has not been fully elucidated but may relate to the peptide's modulation of p53 and apoptotic pathways.

Cardiovascular Complications of Viral Infections

Evidence level: Theoretical/Review

Cardiogen was discussed in a 2020 review on peptide bioregulators as a potential cardioprotective agent in the context of cardiovascular complications associated with viral infections, including COVID-19 [9]. No clinical data supporting this application have been published.

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. Cardiogen is not approved for human use in any regulatory jurisdiction, and no human dosing studies have been published in peer-reviewed literature.

Commonly Referenced Protocols

In the bioregulator supplement community, Cardiogen is typically sold as oral capsules at 200-400 mcg per dose, taken for courses of 10-30 days and repeated 2-3 times annually. This protocol derives from the Russian peptide supplement framework established by Khavinson rather than from controlled dose-finding studies with AEDR specifically. No pharmacokinetic data exist to confirm oral bioavailability of this tetrapeptide.

6. Safety and Side Effects

Published Safety Data

No adverse effects have been reported in published Cardiogen preclinical studies. In organotypic tissue cultures at picomolar concentrations, the peptide stimulated normal cardiomyocyte proliferation without evidence of dysregulated growth [1][2]. As a tetrapeptide composed of common L-amino acids (alanine, glutamic acid, aspartic acid, arginine), it is expected to undergo normal proteolytic degradation.

Critical Safety Gaps

Formal toxicology data meeting international regulatory standards is entirely absent:

• No dose-escalation or maximum tolerated dose studies in any species
• No reproductive or developmental toxicity studies
• No pharmacokinetic studies (absorption, distribution, metabolism, elimination)
• No drug interaction studies, particularly with cardiovascular medications
• No assessment of effects in the setting of active cardiac pathology (ischemia, heart failure, arrhythmia)
• The p53 suppression mechanism raises theoretical oncogenicity concerns that have not been systematically evaluated
• All safety observations derive from Khavinson's research group

p53 Suppression Considerations

Cardiogen's suppression of p53 protein expression warrants careful consideration [1]. While reduced p53 activity may protect against cardiomyocyte apoptosis, p53 is a critical tumor suppressor. Any agent that broadly suppresses p53 carries theoretical oncogenicity risk. The available data suggest tissue-specific effects confined to cardiac cells, but this has not been rigorously confirmed across tissue types.

7. Comparison with Related Peptides

Cardiogen (AEDR) vs. Epithalon (AEDG)

Both share the Ala-Glu-Asp core sequence but differ in the fourth amino acid (Arg vs. Gly). Epithalon targets the pineal gland and activates telomerase, while Cardiogen targets cardiac tissue and promotes cardiomyocyte proliferation. Epithalon has substantially more published research, including primate studies and limited human data, while Cardiogen research remains at the in vitro and small animal model stage.

Cardiogen (AEDR) vs. Bronchogen (AEDL)

Again sharing the Ala-Glu-Asp core, the fourth amino acid (Arg vs. Leu) determines tissue specificity: cardiac vs. bronchial. Both demonstrate p53 suppression and proliferation stimulation in their target tissues. This structural relationship exemplifies Khavinson's proposition that the terminal amino acid determines organ specificity.

Cardiogen vs. Conventional Cardioprotective Agents

Unlike ACE inhibitors, beta-blockers, statins, or anticoagulants used in cardiovascular medicine, Cardiogen does not act through established pharmacological targets. Its proposed mechanism of direct gene expression regulation is fundamentally different from all approved cardiovascular therapies. No comparative efficacy data exist.

8. Limitations and Transparency

The evidence base for Cardiogen has significant limitations:

• All published research originates from Khavinson's institute and affiliated Russian laboratories
• No independent replication by any Western research group
• No human clinical trials of any design have been published
• The key findings (cardiomyocyte proliferation stimulation, p53 suppression) derive from a single in vitro study using organotypic tissue culture
• The molecular mechanism (direct peptide-DNA binding) has not gained acceptance in mainstream molecular biology
• No pharmacokinetic data confirm that oral administration delivers biologically active peptide to cardiac tissue
• Commercial availability as a supplement far exceeds the scientific evidence base

9. Pharmacokinetics

No pharmacokinetic studies have been published for Cardiogen (AEDR). As a tetrapeptide of common L-amino acids, it faces the same fundamental pharmacokinetic challenges as other Khavinson bioregulators: rapid proteolytic degradation, uncertain oral bioavailability, and unknown tissue distribution.

Tetrapeptides are degraded within seconds to minutes in plasma by ubiquitous aminopeptidases, carboxypeptidases, and dipeptidyl peptidases [5][6]. No measurements of intact AEDR concentrations in plasma or cardiac tissue following any route of administration have been published. The oral capsule formulation (200-400 mcg) would need to survive gastric acid, pancreatic proteases, and intestinal brush border peptidases before absorption -- a pharmacokinetic barrier that is essentially unaddressed for this peptide.

Even if some intact peptide reaches systemic circulation, delivery to cardiomyocytes requires transit through the coronary vasculature and penetration of the cardiac cell membrane. The Khavinson group proposes that ultrashort peptides freely penetrate cell membranes and nuclear membranes [11], but this has been demonstrated only in cell culture systems (HeLa cells), not in intact cardiac tissue with its unique extracellular matrix and endothelial barriers.

The picomolar concentrations (10 to the minus 12 M) at which Cardiogen showed activity in organotypic tissue culture [1] are orders of magnitude below what would be expected from oral dosing of microgram quantities. Whether such concentrations are achievable in vivo remains unknown.

10. Dose-Response

No dose-response relationship has been established for Cardiogen in any experimental system. The key in vitro finding -- cardiomyocyte proliferation stimulation and p53 suppression -- was observed at a single concentration (10 to the minus 12 M) in organotypic tissue culture [1]. Whether higher or lower concentrations produce greater, lesser, or qualitatively different effects is unknown.

The standard oral protocol (200-400 mcg per day for 10-30 days) derives from the general Khavinson bioregulator framework rather than from Cardiogen-specific dose optimization [5][6]. No studies have compared different doses for any cardiovascular endpoint. The absence of pharmacokinetic data makes it impossible to correlate oral doses with tissue-level concentrations, rendering dose-response predictions speculative.

In the tissue culture studies, the individual amino acids comprising AEDR (alanine, glutamic acid, aspartic acid, arginine) were tested at the same 10 to the minus 12 M concentration and showed no cardiomyocyte proliferative effect [1]. This critical negative control demonstrates that the intact tetrapeptide sequence is required, but does not address whether dose-response curves exist for the intact peptide.

11. Comparative Effectiveness

Cardiogen (AEDR) vs. Epithalon (AEDG)

Both share the Ala-Glu-Asp core, differing only at position 4 (Arg vs. Gly). Epithalon has a substantially larger evidence base including primate studies, telomerase activation data, human clinical observations, and a 2025 independent replication of telomere elongation. Cardiogen's evidence is limited to in vitro tissue culture from a single research group [1][2]. While Epithalon has documented systemic geroprotective effects, Cardiogen's claimed cardiac specificity has not been validated beyond organotypic cultures.

Cardiogen vs. Bronchogen (AEDL)

Both share the AED core and demonstrate p53 suppression and proliferation stimulation in their respective target tissues [1][4]. Bronchogen has more extensive gene expression characterization (NKX2-1, MUC4, MUC5AC, SFTPA1) and animal model data (COPD mice), while Cardiogen lacks animal efficacy studies entirely. This comparison exemplifies the pattern where the fourth amino acid purportedly determines organ specificity.

Cardiogen vs. Conventional Cardioprotective Agents

Standard cardiovascular therapies (ACE inhibitors, beta-blockers, statins, SGLT2 inhibitors) are supported by massive RCT datasets demonstrating mortality reduction in thousands to tens of thousands of patients. Cardiogen has zero human data and operates through an entirely different proposed mechanism. The comparison underscores the vast evidence gap between Cardiogen and any approved cardiovascular therapy.

12. Enhanced Safety

No adverse effects have been reported in any published Cardiogen study [1][2]. As a tetrapeptide of common L-amino acids, it is expected to undergo normal proteolytic degradation without accumulation or novel metabolite generation.

The p53 suppression mechanism warrants specific safety consideration [1]. P53 is the most frequently mutated tumor suppressor in human cancers, and its inactivation is a hallmark of malignant transformation. While Cardiogen's p53 suppression has been observed only in cardiac tissue culture at picomolar concentrations, the potential for off-target p53 suppression in non-cardiac tissues has not been evaluated. No carcinogenicity or genotoxicity studies have been conducted.

Additional safety concerns specific to cardiac-targeting preparations include the potential for arrhythmogenicity (any agent affecting cardiomyocyte proliferation could theoretically disrupt electrical conduction pathways), interference with endogenous cardiac remodeling processes, and interactions with cardiovascular medications. None of these have been studied.

The absence of any human safety data -- not even an observational case series -- places Cardiogen among the least safety-characterized Khavinson peptides. All safety inferences derive from short-duration in vitro experiments conducted exclusively within Khavinson's research network. Independent toxicological assessment is entirely absent.

13. Related Peptides

See also: Epithalon, Thymalin, Bronchogen

14. References

1. [1] Chalisova NI, Koncevaya EA, Linkova NS, Khavinson VKh. (2009). The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Advances in Gerontology (Uspekhi Gerontologii). PubMed
2. [2] Chalisova NI, Linkova NS, Zhekalov AN, Orlova AN, Ryzhak GA, Khavinson VKh. (2006). Tissue-specific effect of synthetic peptide bioregulators in organotypic tissue cultures in young and old rats. Advances in Gerontology (Uspekhi Gerontologii). PubMed
3. [3] Khavinson VKh, Linkova NS, Diatlova AS, Trofimova SV. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports. DOI PubMed
4. [4] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
5. [5] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
6. [6] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
7. [7] Levdik NV, Knyazkin IV. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of Experimental Biology and Medicine.
8. [8] Khavinson VKh, Tarnovskaia SI, Linkova NS, Guton EO, Elashkina EV. (2014). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology (Uspekhi Gerontologii).
9. [9] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
10. [10] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
11. [11] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
12. [12] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Advances in Gerontology (Uspekhi Gerontologii). PubMed
13. [13] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
14. [14] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed
15. [15] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klin Med (Mosk).